<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059162</url>
  </required_header>
  <id_info>
    <org_study_id>PCL-34-003 (03)</org_study_id>
    <nct_id>NCT01059162</nct_id>
  </id_info>
  <brief_title>Evaluation of OT-135P (IOPtiMateTM) : Beam Manipulating System for CO2 Laser Assisted Non-Penetrating Glaucoma Surgery</brief_title>
  <official_title>Evaluation of OT-135P (IOPtiMateTM) : Beam Manipulating System for CO2 Laser Assisted Non-Penetrating Glaucoma Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IOPtima Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IOPtima Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the safety and effectiveness of the IOPtiMate (OT-135P)&#xD;
      in Laser Assisted Non-Penetrating Glaucoma surgery in Open-Angle and Pseudoexfoliative&#xD;
      Glaucoma patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-Ocular Pressure (IOP)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of anti-Glaucoma Medications</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Pseudo-Exfoliative Glaucoma</condition>
  <arm_group>
    <arm_group_label>IOPtiMate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will undergo non-penetrating laser assisted filtering surgery by the IOPtiMate (OT-134) system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser Assisted Non-penetrating glaucoma surgery</intervention_name>
    <description>A layer by Layer ablation of the deep sclera (under the superficial scleral flap) to achieve functional fluid percolation of the inner eye humor without penetration.</description>
    <arm_group_label>IOPtiMate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must be 18 years of age or older.&#xD;
&#xD;
          2. Patient must have primary open angle glaucoma or pseudo-exfoliative glaucoma in the&#xD;
             study eye; diagnosis is based on glaucomatous optic neuropathy, Shaffer angle of +2&#xD;
             and visual field defect attributed to glaucoma (at least two consecutive abnormal&#xD;
             visual field test results, defined as a pattern SD (PSD) outside the 95% normal&#xD;
             confidence limits and/or glaucoma Hemifield Test (Carl Zeiss Meditec, Inc.).&#xD;
&#xD;
          3. Eye to be treated must be phakic or pseudophakic eye with no ocular disorder or ocular&#xD;
             diseases but cataract, and no prior surgical intervention in study eye but cataract&#xD;
             surgery with clear corneal incision and trabeculoplasty performed &gt; 3 months ago.&#xD;
&#xD;
          4. Patient is indicated for filtration surgery.&#xD;
&#xD;
          5. Presence of ocular hypertension, defined as an intraocular corrected pressure (IOP) ≥&#xD;
             21 mm Hg in the study eye, while on maximal tolerated medications . This IOP level of&#xD;
             above or equal 21 mmHg must be verified and recorded in the most recent 2 consecutive&#xD;
             measurements (but not taken on the same day) prior to operation.&#xD;
&#xD;
          6. Best corrected visual acuity (BCVA) better than 20/200 in the fellow eye.&#xD;
&#xD;
          7. Optic neuropathy is attributed exclusively to glaucoma.&#xD;
&#xD;
          8. Patient or legal guardian agrees to sign written informed consent prior to study&#xD;
             participation.&#xD;
&#xD;
          9. Patient is able and willing to complete post-operative follow-up requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has previously undergone a non-penetrating glaucoma surgery with the IOPtima&#xD;
             CO2 Laser System in fellow eye.&#xD;
&#xD;
          2. Diagnosis of glaucoma other than primary open angle glaucoma or pseudo-exfoliative&#xD;
             glaucoma.&#xD;
&#xD;
          3. History of previous intraocular surgery in the study eye; referring to but not limited&#xD;
             to glaucoma filtering surgery (penetrating and non-penetrating), laser gonioplasty,&#xD;
             corneal transplant, and history of any other laser ocular procedures except for laser&#xD;
             trabeculoplasty surgery.&#xD;
&#xD;
          4. Laser trabeculoplasty surgery within the last three months in the study eye.&#xD;
&#xD;
          5. Study eye is aphakic.&#xD;
&#xD;
          6. Patients with previous cataract extraction with scleral tunnel and or conjunctival&#xD;
             incision in the study eye.&#xD;
&#xD;
          7. Proliferative or severe non-proliferative retinopathy in either eye.&#xD;
&#xD;
          8. Eyes with (dilated) pupil diameter of less than 2 mm in the study eye.&#xD;
&#xD;
          9. Discernable congenital anomaly of the anterior chamber angle in the study eye.&#xD;
&#xD;
         10. Patients with neuropathy other than glaucoma in the study eye.&#xD;
&#xD;
         11. Patient with RVO (retinal vein occlusion) in the study eye.&#xD;
&#xD;
         12. Patient with RAO (retinal artery occlusion) in the study eye.&#xD;
&#xD;
         13. History of prior vitrectomy or Vitreous Hemorrhage (VH) in the study eye.&#xD;
&#xD;
         14. Patient with media opacification which may interfere with optic nerve evaluation in&#xD;
             the study eye.&#xD;
&#xD;
         15. Patient with a history of severe eye trauma in the study eye&#xD;
&#xD;
         16. Patient with ocular malformations such as microphthalmia in the study eye.&#xD;
&#xD;
         17. Patient with concurrent inflammatory / infective eye disorder (e.g. episcleritis,&#xD;
             scleritis) in the study eye&#xD;
&#xD;
         18. Patient with any sign of past or present uveitis (anterior / posterior)&#xD;
&#xD;
         19. Patient with known allergy to the study medications.&#xD;
&#xD;
         20. Patient with severe systemic disease or disabling conditions such as: chronic renal&#xD;
             failure requiring dialysis, severe and disenabling neurological disease, and post&#xD;
             organ transplants.&#xD;
&#xD;
         21. Patient participating in another clinical trial or participation in another clinical&#xD;
             trial is &lt; 3 months.&#xD;
&#xD;
         22. Patient is pregnant or breast feeding. Women of child bearing age will submit a urine&#xD;
             sample result for β-HCG (Pregnancy test) within 2 weeks of surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noa Geffen, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glaucoma service, Ophthalmology ward, Meir Hospital, Kfar-Saba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shlomo Melamed, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glaucoma service, Ophthalmology ward, Sheba Hospital, Tel-Hashomer Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmology ward, Meir Hospital</name>
      <address>
        <city>Kfar-Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2010</study_first_posted>
  <last_update_submitted>June 7, 2011</last_update_submitted>
  <last_update_submitted_qc>June 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dan Peres, COO</name_title>
    <organization>IOPtima Ltd.</organization>
  </responsible_party>
  <keyword>Glaucoma Surgery</keyword>
  <keyword>Filtering Surgery</keyword>
  <keyword>Non Penetrating glaucoma surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

